Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment

Hadassah Medical Center

Status and phase: Withdrawn; Phase 1

Conditions: MS Patient With Relpasing Remitting Attacks

Treatments: Drug: Dexamethasone soduim phosphate

Study type: Interventional

Funder types: Other

Identifiers

NCT00674141

MS089-HMO-CTIL

Details and patient eligibility

About

The study aims to assess the safety and efficacy of nasale administration of Dexamethasone in relapsing MS patients

Enrollment: 10 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• MS patients with esatblished relapsing remitting attacks
• increase in EDSS of at least 1 point for a least one day

Exclusion criteria

• children under 18
• pregnant patients
• patients with diabetes
• known allergy to steroids
• patients who received steroids within 3 months prior to the study

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

1

Other group

Description:

only one experimental treated group

Treatment:

Drug: Dexamethasone soduim phosphate